ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer
New guidelines recommend against retreatment with poly (ADP-ribose) polymerase (PARP) inhibitors in women with epithelial ovarian, tubal, or primary peritoneal cancer (EOC).Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
More News: Allergy | Allergy & Immunology | Cancer | Cancer & Oncology | Epithelial Cancer | Hematology | Ovarian Cancer | Ovaries | Peritoneal Cancer | Women